Experience the OCT difference.
Request your Abbott Sales rep today.
ILUMIEN IV is the largest global imaging randomized clinical trial with n=2,487 patients in 80 global centers. The trial compared OCT-guided stent implantation vs. angiography guided in high-risk or complex lesions. Primary endpoint was achieving larger post-PCI lumen dimensions and improving clinical outcomes.
OCT-guided PCI significantly reduced stent thrombosis (ST) by 64%
No statistical difference in TVF between OCT-guided and angio-guided PCI at 2 years
ILUMIEN IV Substudy: Complex Lesions aimed to specifically examine if OCT-guided PCI improves procedural and clinical outcomes compared with angio-guided PCI outcomes in the complex angiographic lesions subgroup (N=1,973)
OCT-guided PCI reduced serious MACE (Cardiac Death, TV-MI, or Stent Thrombosis) compared with angio-guided PCI at 2 years (p=0.042)3
OCT-guided PCI led to a larger MSA ( 5.56 ± 1.95 mm 5.26 ± 1.81 mm2; p< 0.001) compared to angio-guided PCI3
CALIPSO Trail (Calcified Lesion Intervention Planning Steered by OCT) is the first controlled randomized trial (n=134) that compared OCT-guided PCI to angio-guided PCI in moderate to severe calcified lesions using pre-defined algorithm for plaque modification, stent sizing and optimization.
OCT-guided PCI was superior to angio-guided PCI with greater MSA 6.5 (5.5-8.1) vs. 5.0 (4.1-6.1) mm2, p<0.0014.
OCT-guided PCI achieved greater stent expansion and lower malapposition than angio-guided PCI4
OCT guidance group (n=65) | Angio guidance group (n=69) | p | |
---|---|---|---|
Stent length, mm | 33.0 (24.0-48.0) | 38.0 (25.0-48.0) | 0.35 |
Average stent area, mm2 | 8.4 (7.0-10.3) | 7.4 (6.4-8.6) | 0.01 |
Successful geometrical expansion, n (%) | 49 (75) | 20 (29) | <0.001 |
Major malapposition, n (%) | 23 (35) | 34 (49) | 0.10 |
Malapposition maximal distance, µm | 535 (352-700) | 570 (330-790) | 0.13 |
Major malapposition length, mm | 0 (0-2) | 0 (0-4) | 0.03 |
Malapposed stent percentage, % | 0 (0-8.3) | 0 (0-14.5) | 0.02 |
Average stent eccentricity | 1.21 (1.16-1.25) | 1.19 (1.17-1.24) | 0.87 |
Maximal stent eccentricity | 1.43 (1.35-1.55) | 1.51 (1.36-1.60) | 0.47 |
Major dissection, n (%) | 7 (11) | 13 (19) | 0.19 |
Source: Amabile N., et al. OCT vs. angiography for guidance of calcified lesions PCI: the CALIPSO (CAlcified Lesion Intervention Planning Steered by OCT) trial. EuroPCR2024.
No difference in contrast use, procedure time & radiation dose between OCT-guided and angio-guided PCI4
OCT guidance group (n=65) | Angio guidance group (n=69) | p | |
---|---|---|---|
Procedure duration, mins | 63 (51-87) | 64 (46-82) | 0.22 |
Fluoroscopy duration, mins | 17 (11-21) | 17 (12-27) | 0.95 |
Total X ray dose, cGy/cm2 | 4148 (2550-7155) | 4403 (2630-7333) | 0.65 |
Contrast medium volume, ml | 180 (140-233) | 184 (150-219) | 0.88 |
Source: Adapted from Amabile N., et al. OCT vs. angiography for guidance of calcified lesions PCI: the CALIPSO (CAlcified Lesion Intervention Planning Steered by OCT) trial. EuroPCR2024.
OCTOBER trial was conducted in 38 heart centres across 13 European countries with n=1,201 patients randomized in a 1:1 ratio to undergo OCT-guided or angiography-guided PCI of bifurcation coronary lesions. A step-wise protocol was use in the OCT arm; in the angiography arm, intravascular ultrasound use was discouraged but could be pursued for left main (LM) PCI.
The primary endpoint was major adverse cardiac events (MACE), defined as a composite of cardiac death, target lesion myocardial infarction (TL-MI), and ischemia-driven target lesion revascularization (ID TLR), after two years.
OCT-guided PCI of complex bifurcation lesions is superior to angiography-guided PCI for major adverse cardiac events at 2 years2
From Evidence to Practice: A Pragmatic Approach to OCT.
Watch Dr. Johnson demonstrate how to apply OCT-guidance to a complex bifurcation case from a participant in the OCTOBER Trial with a highly challenging left main stent.
Multiple other studies of OCT-guided PCI vs. angiography alone suggest that intravascular imaging with OCT is associated with better clinical performance5,7,9
STUDY | SIZE | OUTCOMES |
---|---|---|
CLI-OPCI I (EuroIntervention, 2012) | 335 pts OCT guided vs 335 pts angio-guided | Reduced rate of cardiac death and MACE in patients who underwent OCT-guided stent intervention.5 |
ILUMIEN I (EHJ, 2015) | 418 pts | OCT imaging influenced physician decision-making pre-PCI in 57% and post-PCI in 27% of all cases.6 |
ILUMIEN III (LANCET, 2016) | 450 pts (158 OCT, 146 IVUS, 146 ANGIO) | OCT- guided PCI resulted in superior stent expansion and procedural success compared to angiography-guided PCI.7 |
DOCTORS (CIRC 2016) | 240 pts NSTEMI | In patients with non-ST-segment elevation acute coronary sydromes, OCT-guided PCI is associated with higher post-procedure FFR than angio-guided PCI.8 |
PAN-LONDON (JACC CARD INT, 2018) | 1,149 pts OCT, 10,971 pts IVUS 75,046 pts angio | OCT-guided PCI was associated with improved procedural outcomes, in-hospital events and long term survival compared with standard angiography-guided PCI.9 |
MAT-2311283 v3.0
INDICATIONS
Applies to OPTIS™ Imaging Systems and Software
The OPTIS™ Software and AptiVue™ E Series Software are intended to be used only with compatible OPTIS™ Imaging Systems.
The OPTIS™ Imaging Systems with a compatible Dragonfly™ Imaging Catheter are intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The compatible Dragonfly™ Imaging Catheters are intended for use in vessels 2.0 to 3.5 mm in diameter. The compatible Dragonfly™ Imaging Catheters are not intended for use in the left main coronary artery or in a target vessel which has undergone a previous bypass procedure.
The OPTIS™ Imaging Systems are intended for use in the catheterization and related cardiovascular specialty laboratories and will further compute and display various physiological parameters based on the output from one or more electrodes, transducers, or measuring devices. The physician may use the acquired physiological parameters, along with knowledge of patient history, medical expertise and clinical judgment to determine if therapeutic intervention is indicated.
Applies to OPTIS™ Next Imaging Systems and Software
The Ultreon™ 1.0 Software and Ultreon™ 2.0 Software are intended to be used only with compatible OPTIS™ Next Imaging Systems.
The OPTIS™ Next Imaging System with a compatible Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is intended for use in vessels 2.0 to 3.5 mm in diameter. The Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is not intended for use in the left main coronary artery or in a target vessel which has undergone a previous bypass procedure.
The OPTIS™ Next Imaging Systems are intended for use in the catheterization and related cardiovascular specialty laboratories and will further compute and display various physiological parameters based on the output from one or more electrodes, transducers, or measuring devices. The physician may use the acquired physiological parameters, along with knowledge of patient history, medical expertise, and clinical judgment to determine if therapeutic intervention is indicated.
Applies to both OPTIS™ and OPTIS™ Next Imaging Systems and Software
The Dragonfly™ OPTIS™ or Dragonfly™ OpStar™ Imaging Catheters are intended for use in vessels 2.0 to 3.5 mm in diameter. The Dragonfly™ OPTIS™ or Dragonfly™ OpStar™ Imaging Catheters are not intended for use in the left main coronary artery or in a target vessel which has undergone a previous bypass procedure.
The OPTIS™ and OPTIS™ Next Imaging Systems are intended for use in the catheterization and related cardiovascular specialty laboratories and will further compute and display various physiological parameters based on the output from one or more electrodes, transducers, or measuring devices. The physician may use the acquired physiological parameters, along with knowledge of patient history, medical expertise, and clinical judgment to determine if therapeutic intervention is indicated.
CONTRAINDICATIONS
The OPTIS™ and OPTIS™ Next Integrated Systems and Mobile Systems with the usage of the OPTIS™ Software, AptiVue™ E Series Software, Ultreon™ 1.0 Software, and Ultreon™ 2.0 Software are contraindicated where introduction of any catheter would constitute a threat to patient safety. Contraindications include:
COMPLICATIONS
The following complications may occur as a consequence of intravascular imaging and catheterization procedure:
WARNINGS
PRECAUTIONS
MAT-2309288 v1.0
Stay Connected